Top

Published in:

Open Access 01-12-2017 | Research article

Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma

Authors: Laurens G. L. Sand, Tessa Buckle, Fijs W. B. van Leeuwen, Willem E. Corver, Alwine B. Kruisselbrink, Aart G. Jochemsen, Pancras C. W. Hogendoorn, Károly Szuhai

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

Ewing sarcoma is an aggressive, highly metastatic primary bone and soft tissue tumor most frequently occurring in the bone of young adolescents. Patients, especially those diagnosed with a metastatic disease, have a poor overall survival. Chemokine receptor CXCR4 has a key pro-tumorigenic role in the tumor microenvironment of Ewing sarcoma and has been suggested to be involved in the increased metastatic propensity. Earlier studies on CXCR4 protein expression in Ewing sarcoma yielded contradictory results when compared to CXCR4 RNA expression studies. Previously, we demonstrated that CXCR4 expression could be detected in vivo using the fluorescently tagged CXCR4-specific peptide MSAP-Ac-TZ14011. Therefore, we studied the membranous CXCR4 expression in Ewing sarcoma cell lines using MSAP-Ac-TZ14011.

Methods

The CXCR4 membrane expression levels were studied in EWS cell lines by flow cytometry using the hybrid peptide MSAP-Ac-TZ14011 and were correlated to CXCR4 RNA expression levels. The measurements were compared to levels detected using the CXCR4 antibody ab2074 under various cell preparation conditions. In addition, the staining patterns were analyzed by confocal fluorescence microscopy over time.

Results

The hybrid peptide MSAP-Ac-TZ14011 levels showed a strong and better correlation of CXCR4 membrane expression with the CXCR4 RNA expression levels than observed with the anti-CXCR4 antibody ab2074. With the hybrid peptide MSAP-Ac-TZ14011 using live cell confocal microscopy CXCR4 membrane staining and internalization was detected and the signal intensity correlated well with CXCR4 mRNA expression levels.

Conclusions

The fluorescently labeled CXCR4 targeting peptide-based method provides a reliable alternative to antibody staining to study the CXCR4 membrane expression in live cells using either flow cytometry or live cell fluorescence microscopy. The fluorescently tagged CXCR4 targeting peptide could enable in vivo detection of CXCR4 expression in Ewing sarcoma which may help to stratify cases for anti-CXCR4 therapy.

Available only for authorised users

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.CrossRefPubMedPubMedCentral

Bruno A, Pagani A, Magnani E, Rossi T, Noonan D, Cantelmo A, Albini A: Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention. In: Advances in Nutrition and Cancer. Volume 159, edn. Edited by Zappia V, Panico S, Russo GL, Budillon A, Della Ragione F: Springer Berlin Heidelberg; 2014: 401–426.

Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–12.CrossRefPubMedPubMedCentral

Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):27–39.CrossRefPubMed

Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2015;

Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, Walenkamp AME. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30.CrossRefPubMed

Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.CrossRefPubMed

Bennani-Baiti IM, Cooper A, Lawlor ER, Kauer M, Ban J, Aryee DNT, Kovar H. Intercohort Gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res. 2010;16(14):3769–78.CrossRefPubMedPubMedCentral

Berghuis D, Schilham MW, Santos SJ, Savola S, Knowles H, Dirksen U, Schaefer K-L, Vakkila J, Hogendoorn PCW, Lankester AC. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin Sarc Res. 2012;2(1):24.CrossRef

10.

Sand LGL, Scotlandi K, berghuis D, Snaar-Jagalska BE, Picci P, Schmidt T, Szuhai K, Hogendoorn PCW: CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients Eur J Cancer 2015, 51(17):2624–2633.

11.

van den Berg H, Kroon HM, Slaar A, Hogendoorn PCW. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration "PALGA". J Pediatr Orthop. 2008;28(1):29–35.CrossRefPubMed

12.

De Alava E, Lessnick SL, Sorensen PH: Ewing sarcoma. In: WHO Classification of Tumors of Soft Tissue and Bone. 4 edn. Edited by Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. Lyon: IARC; 2013: 306–309.

13.

Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, et al. Primary disseminated multifocal Ewing sarcoma: results of the euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.CrossRefPubMed

14.

Le Deley M-C, Delattre O, Schaefer K-L, Burchill SA, Koehler G, Hogendoorn PCW, Lion T, Poremba C, Marandet J, Ballet S, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative euro-EWING 99 trial. J Clin Oncol. 2010;28(12):1982–8.CrossRefPubMed

15.

Na I-K, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U, Coupland SE. Nuclear expression of CXCR4 in tumor cells of non–small cell lung cancer is correlated with lymph node metastasis. Hum Pathol. 2008;39(12):1751–5.CrossRefPubMed

16.

Brault L, Rovo A, Decker S, Dierks C, Tzankov A, Schwaller J. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia. 2014;28(3):566–76.CrossRefPubMed

17.

Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S. Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One. 2008;3(12):e4069.CrossRefPubMedPubMedCentral

18.

Kuil J, Buckle T, van Leeuwen FWB. Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev. 2012;41(15):5239–61.CrossRefPubMed

19.

Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998;253(3):877–82.CrossRefPubMed

20.

Kuil J, Buckle T, Oldenburg J, Yuan H, Josephson L, van Leeuwen FWB. Hybrid peptide dendrimers for imaging of CXCR4 expression. Mol Pharm. 2011;8(6):2444–53.CrossRefPubMedPubMedCentral

21.

Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33(4):489–94.CrossRefPubMed

22.

van den Berg NS, Buckle T, Kuil J, Wesseling J, van Leeuwen FWB. Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist ac-TZ14011-FITC. Transl Oncol. 2011;4(4):234–40.CrossRefPubMedPubMedCentral

23.

Boulais PE, Dulude D, Cabana J, Heveker N, Escher E, Lavigne P, Leduc R. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site. Biochem Pharmacol. 2009;78(11):1382–90.CrossRefPubMed

24.

Buckle T, Kuil J, van den Berg NS, Bunschoten A, Lamb HJ, Yuan H, Josephson L, Jonkers J, Borowsky AD, van Leeuwen FWB. Use of a single hybrid imaging agent for integration of target validation with In Vivo and Ex Vivo imaging of mouse tumor lesions resembling human DCIS. PLoS One. 2013;8(1):e48324.CrossRefPubMedPubMedCentral

25.

Szuhai K, Ijszenga M, Tanke HJ, Rosenberg C, Hogendoorn PCW. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genet Cytogenet. 2006;166(2):173–9.CrossRefPubMed

26.

Ottaviano L, Schaefer K-L, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 2010;49(1):40–51.CrossRefPubMed

27.

Nijmeijer BA, Szuhai K, Goselink HM, van Schie MLJ, van der Burg M, de Jong D, Marijt EW, Ottmann OG, Willemze R, Falkenburg JHF. Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 2009;37(3):376–85.CrossRefPubMed

28.

Luker KE, Gupta M, Luker GD. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. BioTechniques. 2009;47(1):625–32.CrossRefPubMedPubMedCentral

29.

van Kuppeveld FJ, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl Environ Microbiol. 1992;58(8):2606–15.PubMedPubMedCentral

30.

Kuil J, Velders AH, van Leeuwen FWB. Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. Bioconjug Chem. 2010;21(10):1709–19.CrossRefPubMed

31.

Pelekanos RA, Ting MJ, Sardesai VS, Ryan JM, Lim Y-C, Chan JKY, Fisk NM. Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells. BMC Cell Biol. 2014;15:15–5.

32.

Krook MA, Nicholls LA, Scannell CA, Chugh R, Thomas DG, Lawlor ER. Stress-induced CXCR4 promotes migration and invasion of Ewing sarcoma. Mol Cancer Res. 2014;12(6):953–64.CrossRefPubMedPubMedCentral

33.

Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2008;23(1):43–52.CrossRefPubMed

34.

Sand LGL, Jochemsen AG, Beletkaia E, Schmidt T, Hogendoorn PCW, Szuhai K. Novel splice variants of CXCR4 identified by transcriptome sequencing. Biochem Biophys Res Commun. 2015;466(1):89–94.CrossRefPubMed

35.

Ziarek JJ, Getschman AE, Butler SJ, Taleski D, Stephens B, Kufareva I, Handel TM, Payne RJ, Volkman BF. Sulfopeptide probes of the CXCR4/CXCL12 Interface reveal oligomer-specific contacts and chemokine Allostery. ACS Chem Biol. 2013;8(9):1955–63.CrossRefPubMedPubMedCentral

36.

Rapp C, Snow S, Laufer T, McClendon CL. The role of tyrosine sulfation in the dimerization of the CXCR4:SDF-1 complex. Protein Sci. 2013;22(8):1025–36.CrossRefPubMedPubMedCentral

37.

Zhou N, Luo Z, Luo J, Liu D, Hall JW, Pomerantz RJ, Huang Z. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem. 2001;276(46):42826–33.CrossRefPubMed

38.

Wang J, Babcock GJ, Choe H, Farzan M, Sodroski J, Gabuzda D. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology. 2004;324(1):140–50.CrossRefPubMed

39.

Kuil J, Buckle T, Yuan H, van den Berg NS, Oishi S, Fujii N, Josephson L, van Leeuwen FWB. Synthesis and evaluation of a Biomodal CXCR4 antagonistic peptide. Bioconjug Chem. 2011;22(5):859–64.CrossRefPubMedPubMedCentral

40.

Buckle T, van den Berg NS, Kuil J, Bunschoten A, Oldenburg J, Borowsky AD, Wesseling J, Masada R, Oishi S, Fujii N, van Leeuwen FWB. Non-invasive longitudinal imaging of tumor progression using an111indium labeled CXCR4 peptide antagonist. Am J Nucl Med Mol Imaging. 2012;2(1):99–109.PubMed

41.

Vag T, Gerngoss C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57(6):741–6.CrossRefPubMed

Title: Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma
Authors: Laurens G. L. Sand
Tessa Buckle
Fijs W. B. van Leeuwen
Willem E. Corver
Alwine B. Kruisselbrink
Aart G. Jochemsen
Pancras C. W. Hogendoorn
Károly Szuhai
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3352-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Correction to: Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study

JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression

Thoracoscopic and hand assisted laparoscopic esophagectomy with radical lymph node dissection for esophageal squamous cell carcinoma in the left lateral decubitus position: a single center retrospective analysis of 654 patients

The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients

Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1

Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids

Keynote webinar | Spotlight on antibody–drug conjugates in cancer